Vycor Medical GAAP EPS of $0.00, revenue of $0.41M

Vycor Medical reported Q3 GAAP EPS of $0.00 and revenue of $0.41M, down 19.6% year-over-year, according to the company's press release.

Original reporting
Published Nov 16, 2026, 6:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 6:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VYCO
Bearish
medium confidence
Mentioned
$VYCO
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$VYCOBearishLow
01

Why it matters

The earnings miss is likely to trigger short‑term selling pressure on VYCO.

02

Market read

Micro‑cap earnings release with weak numbers; limited broader market relevance.

03

What to watch

Potential upcoming regulatory approvals or partnership announcements could offset the weak quarter.

Relevance 6/10Novelty 6/10Timing: post‑market release today

Background

Vycor Medical (VYCO) released its Q3 2026 GAAP earnings, reporting zero EPS and a modest revenue decline.

Company-level read

Ticker impact

$VYCOBearishMedium confidence
Context

Q3 GAAP EPS of $0.00 and revenue of $0.41M, down 19.6% YoY.

Expected impact

likely downward pressure as market prices in weak results

Evidence & confidence

Micro‑cap earnings with no profit and revenue contraction typically trigger sell‑offs.

Market effects

Minimal impact on broader biotech sector due to small size.

Negligible effect on US markets overall.

Limited to investors tracking micro‑cap biotech stocks.

Counterpoint

If the company has pipeline catalysts not reflected in Q3, the drop may be overblown.

Key entities

  • Vycor Medical, Inc.

    US‑listed biotech firm reporting Q3 results.

Related articles

$VYCOMed

Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026 BOCA RATON, FL (November 13, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and nine months ended September 30, 2026.

$VYCOMed

Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026 BOCA RATON, FL (August 14, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and six months ended June 30, 2026. The Company op